Complete History of GLP-1 Medications: 1987-2026

The story of GLP-1 medications spans nearly four decades, from a basic science discovery in a university lab to a global revolution in how we treat obesity. Today, semaglutide, tirzepatide, and retatrutide represent three generations of incretin therapy, with each generation building on the science of the one before. This is how we got here.

The Discovery Era (1987-2000)

The discovery of GLP-1 was itself an incretin story -- researchers studying why oral glucose produced a bigger insulin response than intravenous glucose identified GLP-1 as one of the key "incretin" hormones responsible. The challenge was that natural GLP-1 lasted only minutes in the bloodstream. The Gila monster breakthrough -- finding a naturally DPP-4 resistant peptide in reptile saliva -- was the key that unlocked pharmaceutical development.

First Generation: Daily Injections (2005-2016)

Saxenda (2014) was a watershed moment -- the first time a GLP-1 medication was approved specifically for obesity, proving the concept that incretin therapy could treat weight, not just diabetes. However, its ~8% average weight loss was modest compared to what would come.

Second Generation: The Semaglutide Era (2017-2023)

The semaglutide era transformed obesity medicine from a niche specialty into mainstream healthcare. The STEP and SURMOUNT trial programs generated unprecedented excitement. Social media amplified awareness. Demand surged, creating shortages that enabled compounding pharmacies to legally produce these medications -- making affordable access possible through providers like Trimi ($99/mo semaglutide, $125/mo tirzepatide).

Third Generation: Triple Agonists (2023-Present)

What Comes Next (2027+)

The pipeline is extraordinary. Oral semaglutide for weight loss (higher doses), amycretin (Novo Nordisk's amylin/GLP-1 combination), oral GLP-1/GIP agonists, quad-agonists targeting four receptors, and gene therapy approaches are all in development. Each generation delivers more weight loss with comparable or improved safety profiles. The trajectory suggests that pharmacological treatments approaching bariatric surgery-level results without surgery are within reach.